Electra Therapeutics Inc.
Clinical trials sponsored by Electra Therapeutics Inc., explained in plain language.
-
New hope for rare immune storm: experimental drug ELA026 enters key trials
Disease control Recruiting nowThis study tests an experimental drug called ELA026 for people with secondary hemophagocytic lymphohistiocytosis (sHLH), a rare and life-threatening condition where the immune system becomes dangerously overactive. The drug aims to calm this overreaction by targeting certain immu…
Phase: PHASE2, PHASE3 • Sponsor: Electra Therapeutics Inc. • Aim: Disease control
Last updated May 26, 2026 10:59 UTC
-
New hope for rare blood cancers: experimental drug enters human trials
Disease control Recruiting nowThis early-stage study tests an investigational drug called ELA026 in adults with T/NK cell cancers that have come back or not responded to prior treatments. The main goals are to check safety and find the right dose. About 84 participants will be enrolled across multiple centers…
Phase: PHASE1 • Sponsor: Electra Therapeutics Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC